Molecular pathways of pancreatic carcinogenesis

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 2, 2004, Pages 247-252

  Fernandez Zapico, Martin E ^a   Urrutia, Raul ^a  

^a ST MARY S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLOOXYGENASE 2 INHIBITOR; GEMCITABINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN SYNTHASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN KINASE LKB1; PROTEIN P16INK4A; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CLINICAL TRIAL; DRUG TOLERABILITY; GENE THERAPY; HUMAN; MISMATCH REPAIR; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION;

EID: 23744433866     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.09.003     Document Type: Review

References (40)

1. Jemal, A. et al. (2004) Cancer statistics. CA Cancer J. Clin. 54, 8-29
2. Lowenfels, A.B. and Maisonneuve, P. (2004) Epidemiology and prevention of pancreatic cancer. Jpn. J. Clin. Oncol. 34, 238-244
3. Li, D. et al. (2004) Pancreatic cancer. Lancet 363, 1049-1057
4. Freeman, J.W. et al. (2004) Alterations of cell signaling pathways in pancreatic cancer. Front. Biosci. 9, 1889-1998
5. Bardeesy, N. and Depinho, R. (2002) Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897-909
6. Cowgill, S.M. and Muscarella, P. (2003) The genetics of pancreatic cancer. Am. J. Surg. 186, 279-286
7. Sherr, C.J. (2004) Principles of tumor suppression. Cell 116, 235-246
8. Liu, H. et al. (2004) New roles for the RB tumor suppressor protein. Curr. Opin. Genet. Dev. 1, 55-64
9. Gerdes, B. et al. (2002) p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, and Rb. Ann. Surg. 235, 51-59
10. Ghaneh, P. et al. (2001) Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther. 8, 199-208
11. Calbo, J. et al. (2001) Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther. 8, 740-750
12. Hosotani, R. et al. (2002) Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin. Cancer Res. 8, 1271-1276
13. Siegel, P.M. and Massague, J. (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 11, 807-821
14. Schutte, M. (1999) DPC4/SMAD4 gene alterations in human cancer, and their functional implications. Ann. Oncol. 4, 56-59
15. Rowland-Goldsmith, M.A. et al. (2002) Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol. Cancer Ther. 1, 161-167
16. Duda, D.G. et al. (2003) Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 22, 6857-6864
17. Slee, E.A. et al. (2004) To die or not to die: how does p53 decide? Oncogene 23, 2809-2818
18. Hecht, J.R. (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9, 555-561
19. Pino, S.M. et al. (2004) Novel therapies for pancreatic adenocarcinoma. Curr. Gastroenterol. Rep. 6, 119-125
20. Su, G.H. et al. (1999) Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol. 154, 1835-1840
21. Bardeesy, N. et al. (2002) Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419, 162-167
22. Spicer, J. and Ashworth, A. (2004) LKB1 kinase: master and commander of metabolism and polarity. Curr. Biol. 14, 383-385
23. Klein, A.P. et al. (2004) Familial pancreatic cancer. Cancer J. 7, 266-273
24. Goggins, M. et al. (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56, 5360-5364
25. Hahn, S.A. et al. (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl. Cancer Inst. 95, 214-221
26. Rogers, C.D. et al. (2004) The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol. Ther. 2, 167-169
27. Holbro, T. and Hynes, N.E. (2004) ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44, 195-217
28. Roskoski, R.Jr. (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 319, 1-11
29. Wagner, M. et al. (2001) A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 15, 286-293
30. Miyamoto, Y. et al. (2003) Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3, 565-576
31. Xiong, H.Q. (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemother. Pharmacol. (in press)
32. Moore, P.S. et al. (2003) Genetic abnormalities in pancreatic cancer. Mol. Cancer 2, 7-19
33. Longnecker, D.S. and Terhune, P.G. (1998) What is the true rate of K-ras mutation in carcinoma of the pancreas? Pancreas 17, 323-324
34. Duursma, A.M. and Agami, R. (2003) Ras interference as cancer therapy. Semin. Cancer Biol. 13, 267-273
35. Adjei, A.A. (2001) Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93, 1062-1074
36. Keller, E.T. et al. (2004) The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem. Pharmacol. 68, 1049-1053
37. Sebolt-Leopold, J.S. (2004) MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr. Pharm. Des. 10, 1907-1914
38. Cantley, L.C. (2003) The phosphoinositide 3-kinase pathway. Science 5573, 1655-1669
39. Arlt, A. et al. (2003) Role of NF-kappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22, 3243-5321
40. Chun, K.S. and Surh, Y.J. (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol. 68, 1089-1100